Physician profile
John R Cheregi
NPI 1760632384
$15,326.52
in general payments reported to CMS, 2019-2025
13 companies · $662 in 2025
The $662 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $1,353 · 2021: $5,244 · 2022: $2,181 · 2023: $1,528 · 2024: $3,171 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,950 · Food and Beverage: $1,671 · Travel and Lodging: $551 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,950.00 |
| Food and Beverage | $1,671.31 |
| Travel and Lodging | $550.66 |
| Education | $189.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $7,630.14 | 2020-2024 | Tisseel |
| Medtronic, INC. | $5,605.10 | 2021-2025 | Ligasure, Signia |
| Medical Device Business Services, INC. | $1,057.16 | 2019 | |
| Novo Nordisk INC | $469.59 | 2022-2025 | Wegovy |
| Intuitive Surgical, INC. | $275.86 | 2021-2025 | |
| Covidien LP | $98.80 | 2019-2020 | |
| Ethicon US, LLC | $47.57 | 2019 | |
| Conmed Corporation | $41.67 | 2024 | Airseal |
| Currax Pharmaceuticals LLC | $30.16 | 2024 | Contrave |
| Redhill Biopharma INC. | $24.08 | 2020 | |
| Teleflex LLC | $17.07 | 2021 | |
| Lilly USA, LLC | $15.68 | 2024 | Zepbound |
| Impedimed, INC. | $13.64 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cheregi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.